Table 1.

Characteristics of the 1152 ADNI subjects in this study

Demographics	CN	LMCI	AD
Sample size	362	496	294
Sex (M/F)	177/185	307/189	161/133
Age(yr.)	74.61(+/−5.66)	74.11(+/−7.57)	74.71(+/−7.85)
BMI (kg/m2)	27.04(+/−4.51)	26.49(+/−4.32)	25.87(+/−4.71)
Education(yr.)	16.20(+/−2.79)	15.86(+/−2.91)	15.19(+/−2.99)
APOE ɛ4 +/−	101/261	265/231	193/101
Clinic Assessment
ADAS-Cog total score	5.99(+/−3.04)	11.56(+/−4.50)	19.34(+/−6.75)
Memory function (ADNI_MEM)	0.95(+/−0.53)	−0.05(+/−0.57)	−0.73(+/−0.52)
Executive function (ADNI_EF)	0.74(+/−0.70)	0.014(+/−0.78)	−0.82(+/−0.84)
CSF Pathology
CSF p181-Tau	25.54(+/−14.80)	35.36(+/−17.36)	41.64(+/−19.63)
CSF Aβ1–42	207.67(+/−54.47)	163.48(+/−53.57)	143.64(+/−41.86)

Table 1. Characteristics of the 1152 ADNI participants included in this study

Metabolomics datasets from the Biocrates p180 platform used in the current analyses for the ADNI-1 and ADNI-GO/2 cohorts are available via the Accelerating Medicines Partnership-Alzheimer’s Disease (AMP-AD) Knowledge Portal and can be accessed at http://dx.doi.org/10.7303/syn5592519 (ADNI-1) and http://dx.doi.org/10.7303/syn9705278 (ADNI GO-2). The full complement of clinical and demographic data for the ADNI cohorts are hosted on the LONI data sharing platform and can be requested at http://adni.loni.usc.edu/data-samples/access-data/. Abbreviations: ADAS-Cog, Alzheimers Disease Assessment Scale – Cognitive Subscale; BMI, Body Mass Index; CN, cognitively normal; LMCI, Late Mild Cognitive Impairment; AD, Alzheimer’s Disease; yr., years. APOEε4−/+: non-carriers and carriers of the APOE ε4 allele, ADAS-Cog: Alzheimer’s Disease Assessment Scale-Cognitive Subscale, CSF Aβ1–42: Cerebrospinal fluid Amyloid beta 1–42 protein. CSF p181-Tau: Cerebrospinal fluid phosphorylated Tau protein at threonine 181 (p181tau).